Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 Mar 20

PMID 18350153

Citations 34

Authors

Chad J Creighton

Affiliations

Soon will be listed here.

Abstract

Background: Gene transcription patterns associated with activation of oncogenes Myc, c-Src, beta-catenin, E2F3, H-Ras, HER2, EGFR, MEK, Raf, MAPK, Akt, and cyclin D1, as well as of the cell cycle and of androgen signaling have been generated in previous studies using experimental models. It was not clear whether genes in these "oncogenic signatures" would show coordinate expression patterns in human prostate tumors, particularly as most of the signatures were derived from cell types other than prostate.

Principal Findings: The above oncogenic pathway signatures were examined in four different gene expression profile datasets of human prostate tumors (representing approximately 250 patients in all), using both Q1-Q2 and one-sided Fisher's exact enrichment analysis methods. A significant fraction (approximately 5%) of genes up-regulated experimentally by Myc, c-Src, HER2, Akt, or androgen were co-expressed in human tumors with the oncogene or biomarker corresponding to the pathway signature. Genes down-regulated experimentally, however, did not show anticipated patterns of anti-enrichment in the human tumors.

Conclusions: Significant subsets of the genes in these experimentally-derived oncogenic signatures are relevant to the study of human prostate cancer. Both molecular biologists and clinical researchers could focus attention on the relatively small number of genes identified here as having coordinate patterns that arise from both the experimental system and the human disease system.

Citing Articles

Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway.

Park J, Jung K, Jia D, Yang S, Attri K, Ahn S Cell Rep Med. 2025; 6(2):101941.

PMID: 39933530 PMC: 11866546. DOI: 10.1016/j.xcrm.2025.101941.

Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.

Zhang Y, Chen F, Chandrashekar D, Varambally S, Creighton C Nat Commun. 2022; 13(1):2669.

PMID: 35562349 PMC: 9106650. DOI: 10.1038/s41467-022-30342-3.

The Sca-1 and Sca-1 mouse prostatic luminal cell lineages are independently sustained.

Kwon O, Choi J, Zhang L, Jia D, Li Z, Zhang Y Stem Cells. 2020; 38(11):1479-1491.

PMID: 32627901 PMC: 7606766. DOI: 10.1002/stem.3253.

Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.

Chen F, Chandrashekar D, Varambally S, Creighton C Nat Commun. 2019; 10(1):5679.

PMID: 31831737 PMC: 6908580. DOI: 10.1038/s41467-019-13528-0.

Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

Blundon M, Dasgupta S Endocrinology. 2019; 160(8):1811-1820.

PMID: 31157867 PMC: 6620757. DOI: 10.1210/en.2019-00097.

References

Coller H, Grandori C, Tamayo P, Colbert T, Lander E, Eisenman R . Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000; 97(7):3260-5. PMC: 16226. DOI: 10.1073/pnas.97.7.3260. View

Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A . Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002; 62(15):4427-33. View

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View

Glinsky G, Glinskii A, Stephenson A, Hoffman R, Gerald W . Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004; 113(6):913-23. PMC: 362118. DOI: 10.1172/JCI20032. View

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

DePrimo S, Diehn M, Nelson J, Reiter R, Matese J, Fero M . Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002; 3(7):RESEARCH0032. PMC: 126237. DOI: 10.1186/gb-2002-3-7-research0032. View

Saldanha A . Java Treeview--extensible visualization of microarray data. Bioinformatics. 2004; 20(17):3246-8. DOI: 10.1093/bioinformatics/bth349. View

Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View

Creighton C, Cordero K, Larios J, Miller R, Johnson M, Chinnaiyan A . Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 2006; 7(4):R28. PMC: 1557996. DOI: 10.1186/gb-2006-7-4-r28. View

10.

Hughes C, Murphy A, Martin C, Sheils O, OLeary J . Molecular pathology of prostate cancer. J Clin Pathol. 2005; 58(7):673-84. PMC: 1770715. DOI: 10.1136/jcp.2002.003954. View

11.

Creighton C, Hilger A, Murthy S, Rae J, Chinnaiyan A, El-Ashry D . Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006; 66(7):3903-11. DOI: 10.1158/0008-5472.CAN-05-4363. View

12.

Majumder P, Febbo P, Bikoff R, Berger R, Xue Q, McMahon L . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10(6):594-601. DOI: 10.1038/nm1052. View

13.

Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, Montgomery K . Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; 101(3):811-6. PMC: 321763. DOI: 10.1073/pnas.0304146101. View

14.

Lehmann U, Kreipe H . Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods. 2002; 25(4):409-18. DOI: 10.1006/meth.2001.1263. View

15.

Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix J, Ladd-Acosta C . An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2004; 37(1):48-55. DOI: 10.1038/ng1490. View

16.

Whitfield M, Sherlock G, Saldanha A, Murray J, Ball C, Alexander K . Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002; 13(6):1977-2000. PMC: 117619. DOI: 10.1091/mbc.02-02-0030. View

17.

Lamb J, Ramaswamy S, Ford H, Contreras B, Martinez R, Kittrell F . A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003; 114(3):323-34. DOI: 10.1016/s0092-8674(03)00570-1. View

18.

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

19.

Ellwood-Yen K, Graeber T, Wongvipat J, Iruela-Arispe M, Zhang J, Matusik R . Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003; 4(3):223-38. DOI: 10.1016/s1535-6108(03)00197-1. View

20.

Yu Y, Landsittel D, Jing L, Nelson J, Ren B, Liu L . Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004; 22(14):2790-9. DOI: 10.1200/JCO.2004.05.158. View